# Oxymorphone
*Source: https://go.drugbank.com/drugs/DB01192*

## Overview

### Description

This compound belongs to the class of organic compounds known as phenanthrenes and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene.

### Background

An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation.

### Indication

For the treatment of moderate-to-severe pain.

### Pharmacodynamics

Oxymorphone is a semi-synthetic opioid substitute for morphine. It is a potent analgesic. Opioid analgesics exert their principal pharmacologic effects on the CNS and the gastrointestinal tract. The principal actions of therapeutic value are analgesia and sedation. Opioids produce respiratory depression by direct action on brain stem respiratory centers. The mechanism of respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation.

### Mechanism of Action

Mu-type opioid receptor
Agonist

### Metabolism

Oxymorphone undergoes extensive hepatic metabolism in humans. After a 10 mg oral dose, 49% was excreted over a five-day period in the urine. Of this, 82% was excreted in the first 24 hours after administration. The recovered drug-related products contained the oxymorphone (1.9%), the conjugate of oxymorphone (44.1%), the 6(beta)-carbinol produced by 6-keto reduction of oxymorphone (0.3%), and the conjugates of 6(beta)-carbinol (2.6%) and 6(alpha)-carbinol (0.1%).
Hover over products below to view reaction partners
Oxymorphone
noroxycodone
noroxymorphone
alpha-noroxycodol
beta-noroxycodol
oxymorphone
beta-oxymorphol
alpha-oxycodol
beta-oxycodol

### Half-life

1.3 (+/-0.7) hours

### Toxicity

Oxymorphone overdosage is characterized by respiratory depression, extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. Patients experiencing an overdose may develop apnea, circulatory collapse, and cardiac arrest. Intravenous mouse LD
50
is 172 mg/kg.

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The risk or severity of adverse effects can be increased when Oxymorphone is combined with 1,2-Benzodiazepine.
Abametapir
The serum concentration of Oxymorphone can be increased when it is combined with Abametapir.
Abatacept
The metabolism of Oxymorphone can be increased when combined with Abatacept.
Abiraterone
The metabolism of Oxymorphone can be decreased when combined with Abiraterone.
Acebutolol
The metabolism of Oxymorphone can be decreased when combined with Acebutolol.

### Food Interactions

Avoid alcohol. Ingesting alcohol has unpredictable effects on the pharmacokinetics of oxymorphone. Alcohol may also potentiate the CNS depressant effects of oxymorphone.
Take on an empty stomach. Take oxymorphone at least one hour before or two hours after eating as food may increase the absorption of oxymorphone.

## Chemical Information

**DrugBank ID:** DB01192

**Synonyms:** (14S)-14-Hydroxydihydromorphinone
14-Hydroxydihydromorphinone
Dihydrohydroxymorphinone
Dihydroxymorphinone
Oximorfona
Oximorphonum
Oxymorphone
Oxymorphonum

**Chemical Formula:** C
17
H
19
NO
4

**SMILES:** [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O

**Weight:** Average: 301.3371
Monoisotopic: 301.131408101

**IUPAC Name:** (1S,5R,13R,17S)-10,17-dihydroxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one

## Additional Information

### Modality

Small Molecule

### Patents

Patent Number
Pediatric Extension
Expires (estimated)
Region
US5662933
No
1997-09-02
2013-09-09
US
US7276250
No
2007-10-02
2023-02-04
US
US8309060
No
2012-11-13
2023-11-20
US
US8114383
No
2012-02-14
2024-10-10
US
US8808737
No
2014-08-19
2027-06-21
US
US8871779
No
2014-10-28
2029-11-22
US
US8192722
No
2012-06-05
2025-09-15
US
US8075872
No
2011-12-13
2023-11-20
US
US7851482
No
2010-12-14
2029-07-10
US
US8329216
No
2012-12-11
2023-02-04
US
US8309122
No
2012-11-13
2023-02-04
US
US8309112
No
2012-11-13
2023-02-04
US

### Indicated Conditions

4

### Phase 0

0

### Phase 1

5

### Phase 2

1

### Phase 3

14

### Phase 4

10

### Therapeutic Categories

Opiate
Agonists
Opioid
Agonist

### Summary

Oxymorphone
is an opioid analgesic used in the management of moderate-to-severe pain and for analgesic therapies.

### Brand Names

Opana

### Generic Name

Oxymorphone

### DrugBank Accession Number

DB01192

### Groups

Approved, Vet approved

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Oxymorphone (DB01192)
×
Close

### External IDs

IDS-NO-003
NIH 10323
NSC-19045

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Management of
Anxiety
••••••••••••
Create Account
•••••••••
Management of
Severe pain
••••••••••••
Create Account
•••••••••• ••••••• •••••••• •••••••
Management of
Moderate pain
••••••••••••
Create Account
•••••••••
Create Account

### Associated Therapies

Perioperative analgesia
Obstetrical analgesia therapy

### Mechanism of action

Oxymorphone interacts predominantly with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. Also, it has been shown that oxymorphone binds to and inhibits GABA inhibitory interneurons via mu-receptors. These interneurons normally inhibit the descending pain inhibition pathway. So, without the inhibitory signals, pain modulation can proceed downstream.
Target
Actions
Organism
A
Mu-type opioid receptor
agonist
Humans
U
Delta-type opioid receptor
antagonist
Humans

### Route of elimination

Oxymorphone is highly metabolized, principally in the liver, and undergoes reduction or conjugation with glucuronic acid to form both active and inactive products. Because oxymorphone is extensively metabolized, <1% of the administered dose is excreted unchanged in the urine.

### Pathways

Pathway
Category
Oxymorphone Action Pathway
Drug action

### Product Ingredients

Ingredient
UNII
CAS
InChI Key
Oxymorphone hydrochloride
5Y2EI94NBC
357-07-3
BCGJBQBWUGVESK-KCTCKCTRSA-N

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Numorphan
Injection
1.5 mg/1mL
Parenteral
Endo Pharmaceuticals
1959-05-14
2009-07-31
US
Numorphan
Injection
1 mg/1mL
Parenteral
Endo Pharmaceuticals
1959-05-14
2009-07-31
US
Numorphan
Suppository
5 mg/1
Rectal
Endo Pharmaceuticals
1959-05-14
2009-08-31
US
Numorphan Injection 1.5mg/ml
Liquid
1.5 mg / mL
Intramuscular; Intravenous; Subcutaneous
Bristol Myers Squibb
1993-12-31
2004-08-04
Canada
Numorphan Suppository 5mg
Suppository
5 mg
Rectal
Bristol Myers Squibb
1993-12-31
2002-07-04
Canada

### Generic Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Oxymorphone Hydrochloride
Tablet
5 mg/1
Oral
KVK-Tech, Inc.
2013-02-11
Not applicable
US
Oxymorphone Hydrochloride
Tablet
5 mg/1
Oral
Camber Pharmaceuticals, Inc.
2018-03-01
Not applicable
US
Oxymorphone hydrochloride
Tablet, film coated, extended release
10 mg/1
Oral
Amneal Pharmaceuticals LLC
2013-01-02
Not applicable
US
Oxymorphone Hydrochloride
Tablet
10 mg/1
Oral
Epic Pharma, LLC
2019-05-15
Not applicable
US
Oxymorphone Hydrochloride
Tablet
10 mg/1
Oral
Aurolife Pharma, LLC
2016-04-26
Not applicable
US

### ATC Codes

N02AA11 — Oxymorphone
N02AA — Natural opium alkaloids
N02A — OPIOIDS
N02 — ANALGESICS
N — NERVOUS SYSTEM

### Drug Categories

Adjuvants
Adjuvants, Anesthesia
Alkaloids
Analgesics
Central Nervous System Agents
Central Nervous System Depressants
Cytochrome P-450 CYP2D6 Substrates
Cytochrome P-450 CYP3A Substrates
Cytochrome P-450 CYP3A4 Substrates
Cytochrome P-450 Substrates
Heterocyclic Compounds, Fused-Ring
High-risk opioids
Morphinans
Morphine Derivatives
Narcotics
Natural Opium Alkaloids
Nervous System
Opiate Agonists
Opiate Alkaloids
Opioid Agonist
Opioids
Peripheral Nervous System Agents
Phenanthrenes
Sensory System Agents
Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as phenanthrenes and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenanthrenes and derivatives
Sub Class
Not Available
Direct Parent
Phenanthrenes and derivatives
Alternative Parents
Isoquinolones and derivatives
/
Tetralins
/
Coumarans
/
1-hydroxy-2-unsubstituted benzenoids
/
Alkyl aryl ethers
/
Aralkylamines
/
Piperidines
/
Tertiary alcohols
/
Trialkylamines
/
1,2-aminoalcohols
/
Ketones
/
Cyclic alcohols and derivatives
/
Oxacyclic compounds
/
Azacyclic compounds
/
Organic oxides
/
Hydrocarbon derivatives
/
Organopnictogen compounds
show 7 more
Substituents
1,2-aminoalcohol
/
1-hydroxy-2-unsubstituted benzenoid
/
Alcohol
/
Alkyl aryl ether
/
Amine
/
Aralkylamine
/
Aromatic heteropolycyclic compound
/
Azacycle
/
Carbonyl group
/
Coumaran
/
Cyclic alcohol
/
Ether
/
Hydrocarbon derivative
/
Isoquinolone
/
Ketone
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organoheterocyclic compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Oxacycle
/
Phenanthrene
/
Piperidine
/
Tertiary alcohol
/
Tertiary aliphatic amine
/
Tertiary amine
/
Tetralin
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
morphinane alkaloid (
CHEBI:7865
)

### Kingdom

Organic compounds

### Super Class

Benzenoids

### Class

Phenanthrenes and derivatives

### Direct Parent

Phenanthrenes and derivatives

### Alternative Parents

Isoquinolones and derivatives
/
Tetralins
/
Coumarans
/
1-hydroxy-2-unsubstituted benzenoids
/
Alkyl aryl ethers
/
Aralkylamines
/
Piperidines
/
Tertiary alcohols
/
Trialkylamines
/
1,2-aminoalcohols
/
Ketones
/
Cyclic alcohols and derivatives
/
Oxacyclic compounds
/
Azacyclic compounds
/
Organic oxides
/
Hydrocarbon derivatives
/
Organopnictogen compounds
show 7 more

### Substituents

1,2-aminoalcohol
/
1-hydroxy-2-unsubstituted benzenoid
/
Alcohol
/
Alkyl aryl ether
/
Amine
/
Aralkylamine
/
Aromatic heteropolycyclic compound
/
Azacycle
/
Carbonyl group
/
Coumaran
/
Cyclic alcohol
/
Ether
/
Hydrocarbon derivative
/
Isoquinolone
/
Ketone
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organoheterocyclic compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Oxacycle
/
Phenanthrene
/
Piperidine
/
Tertiary alcohol
/
Tertiary aliphatic amine
/
Tertiary amine
/
Tetralin
show 19 more

### Molecular Framework

Aromatic heteropolycyclic compounds

### External Descriptors

morphinane alkaloid (
CHEBI:7865
)

### Affected organisms

Humans and other mammals

### UNII

9VXA968E0C

### CAS number

76-41-5

### InChI Key

UQCNKQCJZOAFTQ-ISWURRPUSA-N

### InChI

InChI=1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1

### Synthesis Reference

Bao-Shan Huang, Yansong Lu, Ben-Yi Ji, Aris P Christodoulou, "Preparation of oxymorphone from morphine." U.S. Patent US5922876, issued May, 1992.
US5922876

### General References

FDA Approved Drug Products: OPANA® ER (oxymorphone hydrochloride) extended-release tablets, for oral use, CII [
Link
]

### External Links

Human Metabolome Database
HMDB0015323
KEGG Drug
D08323
KEGG Compound
C08019
PubChem Compound
5284604
PubChem Substance
46505296
ChemSpider
4447650
BindingDB
50001707
RxNav
7814
ChEBI
7865
ChEMBL
CHEMBL963
ZINC
ZINC000003875483
Therapeutic Targets Database
DAP001138
PharmGKB
PA450748
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Oxymorphone

### Human Metabolome Database

HMDB0015323

### KEGG Drug

D08323

### KEGG Compound

C08019

### PubChem Compound

5284604

### PubChem Substance

46505296

### ChemSpider

4447650

### BindingDB

50001707

### RxNav

7814

### ChEBI

7865

### ChEMBL

CHEMBL963

### ZINC

ZINC000003875483

### Therapeutic Targets Database

DAP001138

### PharmGKB

PA450748

### RxList

RxList Drug Page

### Drugs.com

Drugs.com Drug Page

### Wikipedia

Oxymorphone

### FDA label

Download
(9.95 MB)

### MSDS

Download
(133 KB)

### Packagers

Bristol-Myers Squibb Co.
DSM Corp.
Endo Pharmaceuticals Inc.
Lake Erie Medical and Surgical Supply
Novartis AG
Nucare Pharmaceuticals Inc.
Quality Care
Stat Rx Usa

### Dosage Forms

Form
Route
Strength
Injection
Parenteral
1 mg/1mL
Injection
Parenteral
1.5 mg/1mL
Suppository
Rectal
5 mg/1
Liquid
Intramuscular; Intravenous; Subcutaneous
1.5 mg / mL
Suppository
Rectal
5 mg
Injection
Intramuscular; Intravenous; Subcutaneous
1 mg/1mL
Tablet
Oral
10 mg/1
Tablet
Oral
20 mg/1
Tablet, extended release
Oral
10 mg/1
Tablet, extended release
Oral
10 mg
Tablet, extended release
Oral
15 mg/1
Tablet, extended release
Oral
20 mg
Tablet, extended release
Oral
20 mg/1
Tablet, extended release
Oral
30 mg/1
Tablet, extended release
Oral
40 mg/1
Tablet, extended release
Oral
40 mg
Tablet, extended release
Oral
5 mg
Tablet, extended release
Oral
5 mg/1
Tablet, extended release
Oral
7.5 mg/1
Tablet, film coated, extended release
Oral
10 mg/1
Tablet, film coated, extended release
Oral
40 mg/1
Tablet, film coated, extended release
Oral
5 mg/1
Tablet
Oral
5 mg/1
Tablet, film coated, extended release
Oral
15 mg/1
Tablet, film coated, extended release
Oral
20 mg/1
Tablet, film coated, extended release
Oral
30 mg/1
Tablet, film coated, extended release
Oral
7.5 mg/1

### Prices

Unit description
Cost
Unit
Opana er 40 mg tablet
21.82USD
tablet
Opana er 30 mg tablet
17.39USD
tablet
Opana ER 40 mg 12 Hour tablet
12.42USD
tablet
Opana er 20 mg tablet
12.12USD
tablet
Opana ER 30 mg 12 Hour tablet
9.76USD
tablet
Opana er 15 mg tablet
9.26USD
tablet
Opana ER 20 mg 12 Hour tablet
7.17USD
tablet
Opana ER 15 mg 12 Hour tablet
5.82USD
tablet
Opana er 5 mg tablet
5.53USD
tablet
Opana ER 10 mg 12 Hour tablet
4.4USD
tablet
Opana er 10 mg tablet
3.95USD
tablet
Opana ER 7.5 mg 12 Hour tablet
3.3USD
tablet
Numorphan 1 mg/ml ampul
3.13USD
ml
Opana er 7.5 mg tablet
3.0USD
tablet
Opana ER 5 mg 12 Hour tablet
2.3USD
tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Solid

### Experimental Properties

Property
Value
Source
melting point (°C)
248-249 °C
PhysProp
water solubility
2.4E+004 mg/L
Not Available
logP
0.83
HANSCH,C ET AL. (1995)
pKa
8.17
SANGSTER (1994)

### Predicted Properties

Property
Value
Source
Water Solubility
25.6 mg/mL
ALOGPS
logP
1.26
ALOGPS
logP
0.78
Chemaxon
logS
-1.1
ALOGPS
pKa (Strongest Acidic)
10.07
Chemaxon
pKa (Strongest Basic)
8.21
Chemaxon
Physiological Charge
1
Chemaxon
Hydrogen Acceptor Count
5
Chemaxon
Hydrogen Donor Count
2
Chemaxon
Polar Surface Area
70 Å
2
Chemaxon
Rotatable Bond Count
0
Chemaxon
Refractivity
79.56 m
3
·mol
-1
Chemaxon
Polarizability
30.77 Å
3
Chemaxon
Number of Rings
5
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
No
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9934
Blood Brain Barrier
+
0.9382
Caco-2 permeable
+
0.7798
P-glycoprotein substrate
Substrate
0.9112
P-glycoprotein inhibitor I
Non-inhibitor
0.8887
P-glycoprotein inhibitor II
Non-inhibitor
0.9734
Renal organic cation transporter
Non-inhibitor
0.5585
CYP450 2C9 substrate
Non-substrate
0.8014
CYP450 2D6 substrate
Substrate
0.8105
CYP450 3A4 substrate
Substrate
0.7439
CYP450 1A2 substrate
Non-inhibitor
0.8796
CYP450 2C9 inhibitor
Non-inhibitor
0.9459
CYP450 2D6 inhibitor
Non-inhibitor
0.7168
CYP450 2C19 inhibitor
Non-inhibitor
0.8455
CYP450 3A4 inhibitor
Non-inhibitor
0.9219
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.9812
Ames test
Non AMES toxic
0.6663
Carcinogenicity
Non-carcinogens
0.9635
Biodegradation
Not ready biodegradable
0.9758
Rat acute toxicity
2.9920 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.9345
hERG inhibition (predictor II)
Non-inhibitor
0.9374
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-0a4l-9050000000-d955cbd739d3bad18756
Mass Spectrum (Electron Ionization)
MS
splash10-0udl-7932000000-89141254d526ca629dac
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0udi-0019000000-e0dd7096a176ae8f16ec
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0udi-0009000000-660fcd4e70fedb35e609
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-001i-0092000000-080ebb4a02005bbb5eb1
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0udi-0009000000-818e15ec502f7c985653
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0fzd-0091000000-30d5f0e0834719718780
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0ue9-0089000000-27ea24fd36b045448647
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0udi-0019000000-e0dd7096a176ae8f16ec
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0udi-0009000000-660fcd4e70fedb35e609
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0udi-0009000000-818e15ec502f7c985653
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-001i-0092000000-080ebb4a02005bbb5eb1
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0fzd-0091000000-30d5f0e0834719718780
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0ue9-0089000000-27ea24fd36b045448647
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
171.7636379
predicted
DarkChem Lite v0.1.0
[M-H]-
170.2621379
predicted
DarkChem Lite v0.1.0
[M-H]-
176.03879
predicted
DeepCCS 1.0 (2019)
[M-H]-
171.7636379
predicted
DarkChem Lite v0.1.0
[M-H]-
170.2621379
predicted
DarkChem Lite v0.1.0
[M-H]-
176.03879
predicted
DeepCCS 1.0 (2019)
[M+H]+
171.8439379
predicted
DarkChem Lite v0.1.0
[M+H]+
170.8877379
predicted
DarkChem Lite v0.1.0
[M+H]+
178.3968
predicted
DeepCCS 1.0 (2019)
[M+H]+
171.8439379
predicted
DarkChem Lite v0.1.0
[M+H]+
170.8877379
predicted
DarkChem Lite v0.1.0
[M+H]+
178.3968
predicted
DeepCCS 1.0 (2019)
[M+Na]+
171.7116379
predicted
DarkChem Lite v0.1.0
[M+Na]+
170.3857379
predicted
DarkChem Lite v0.1.0
[M+Na]+
186.22691
predicted
DeepCCS 1.0 (2019)
[M+Na]+
171.7116379
predicted
DarkChem Lite v0.1.0
[M+Na]+
170.3857379
predicted
DarkChem Lite v0.1.0
[M+Na]+
186.22691
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Substrate

### General Function

A cytochrome P450 monooxygenase involved in the metabolism of fatty acids, steroids and retinoids (PubMed:18698000, PubMed:19965576, PubMed:20972997, PubMed:21289075, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:18698000, PubMed:19965576, PubMed:20972997, PubMed:21289075, PubMed:21576599). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed:19965576, PubMed:20972997). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 20-hydroxyeicosatetraenoic acid ethanolamide (20-HETE-EA) and 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:18698000, PubMed:21289075). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). Catalyzes the oxidative transformations of all-trans retinol to all-trans retinal, a precursor for the active form all-trans-retinoic acid (PubMed:10681376). Also involved in the oxidative metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants

### Specific Function

anandamide 11,12 epoxidase activity

### Gene Name

CYP2D6

### Uniprot ID

P10635

### Uniprot Name

Cytochrome P450 2D6

### Molecular Weight

55768.94 Da

